Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 3:35 AM ET

Pharmaceuticals

Company Overview of Salix Pharmaceuticals Ltd.

Company Overview

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides Xifaxan tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; Apriso to maintain remission of ulcerative colitis (UC); Moviprep and Osmoprep for cleansing of the colon as a preparation for colonoscopy in adults; Relistor for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; Solesta to treat fecal incontinence; and Deflux to treat vesicoureteral reflux. It also offers Fulyzaq for the symptomatic relief of non-infectious diarrhea in adult...

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Founded in 1989

1,000 Employees

Phone:

919-862-1000

Fax:

919-862-1095

Key Executives for Salix Pharmaceuticals Ltd.

Founder and Chief Scientific Liaison
Co-Founder
Age: 59
General Counsel, Executive Vice President, Secretary and Director
Age: 44
Associate Vice President of Investor Relations & Corporate Communications
Compensation as of Fiscal Year 2014.

Salix Pharmaceuticals Ltd. Key Developments

Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from Russell 1000 Index

Salix Pharmaceuticals Ltd. will be removed from Russell 1000 Index.

Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from Russell 3000 Index

Salix Pharmaceuticals Ltd. will be removed from Russell 3000 Index.

Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from S&P 1000 Index

Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from S&P 1000 Index

Similar Private Companies By Industry

Company Name Region
W.F. Young, Inc. United States
Sebela Pharmaceuticals, Inc. United States
Madeira Therapeutics LLC United States
Kos Pharmaceuticals, Inc. United States
Javelin Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 11, 2015
--
Merger/Acquisition
February 22, 2015
--
Merger/Acquisition
July 8, 2014
Cosmo Technologies Ltd
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Salix Pharmaceuticals Ltd., please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.